BioAge Labs (NASDAQ:BIOA) Price Target Cut to $35.00 by Analysts at Needham & Company LLC

BioAge Labs (NASDAQ:BIOA) had its price target reduced by Needham & Company LLC from $50.00 to $35.00 in a research report report published on Friday,Benzinga reports. They currently have a buy rating on the stock.

BIOA has been the topic of several other research reports. Roth Capital reissued a “buy” rating and set a $25.00 target price on shares of BioAge Labs in a research note on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a research note on Tuesday, July 21st. Wall Street Zen lowered shares of BioAge Labs from a “hold” rating to a “sell” rating in a report on Sunday, May 17th. BTIG Research began coverage on shares of BioAge Labs in a research report on Wednesday, May 13th. They set a “buy” rating and a $40.00 price objective on the stock. Finally, Jefferies Financial Group set a $21.00 target price on shares of BioAge Labs in a report on Friday. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $36.57.

BioAge Labs Stock Performance

Shares of BIOA stock opened at $9.04 on Friday. The stock has a fifty day simple moving average of $20.61 and a two-hundred day simple moving average of $19.51. The firm has a market capitalization of $401.83 million, a PE ratio of -3.77 and a beta of 0.61. BioAge Labs has a 52-week low of $4.11 and a 52-week high of $25.95.

BioAge Labs (NASDAQ:BIOA) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.19. The business had revenue of $2.77 million for the quarter. BioAge Labs had a negative return on equity of 29.40% and a negative net margin of 871.75%. On average, sell-side analysts forecast that BioAge Labs will post -2.68 EPS for the current fiscal year.

Hedge Funds Weigh In On BioAge Labs

Institutional investors have recently added to or reduced their stakes in the company. CWM LLC increased its stake in BioAge Labs by 39.9% in the 4th quarter. CWM LLC now owns 3,693 shares of the company’s stock worth $49,000 after acquiring an additional 1,053 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of BioAge Labs by 24.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,808 shares of the company’s stock valued at $196,000 after acquiring an additional 2,917 shares during the last quarter. Barclays PLC boosted its position in shares of BioAge Labs by 9.3% during the 4th quarter. Barclays PLC now owns 37,780 shares of the company’s stock valued at $500,000 after acquiring an additional 3,222 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of BioAge Labs by 46.3% in the third quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock valued at $65,000 after purchasing an additional 3,517 shares in the last quarter. Finally, Russell Investments Group Ltd. purchased a new position in shares of BioAge Labs in the third quarter valued at $27,000.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.